J&J logs $19.5B in Q2 sales

Share this article:
J&J to submit schizophrenia drug in 2014
J&J logs $19.5B in Q2 sales

Hepatitis C medication Olysio's $831 million in second-quarter sales beat analyst expectations, which hovered in the $617 million range, helping power Johnson & Johnson's quarterly revenue total of $19.5 billion, a 9% increase over the same period last year.

Immunology drug Remicade ($1.8 billion), prostate-cancer drug Zytiga ($562 million) and HIV medication Prezista ($492 million) provided tentpoles of sorts, helping bring pharmaceutical sales to $7 billion for the quarter.

Consumer products sales grew 2% compared to the same period last year, with $3.7 billion in sales worldwide. CEO Alex Gorsky noted in an investor call that consumer products are tightly tied to Gross Domestic Product numbers, which are on the rise, and that growing middle classes are gravitating towards its baby care, skin care and dental care lines.

While Gorsky and CFO Dominic Caruso were enthusiastic about the quarter's results, execs tempered expectations, noting that they expect competing hepatitis drugs will put considerable pressure on Olysio. Caruso told investors the second quarter should not be a benchmark because “we do expect that the current run rate is not really sustainable.” Goldman Sachs analyst Jami Rubin wrote in a research note that Gilead's anticipated once-daily combination drug “will likely be priced below Olysio/Sovaldi, which now costs $150,000.” J&J execs said the company was pursuing clinical trials that mixed and matched Olysio with other drugs.

Gorsky also noted that the company's size—J&J has been asked about splitting up ala Pfizer and Abbott—has put the company in a strong position to work with large health system, like hospitals. This is despite the device and diagnostic division's muted quarterly performance.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...